Watson sues US FDA over delay of generic Actos approval
The company’s abbreviated new drug application (ANDA) may be delayed for up to six months following the agency’s decision. Watson has filed a suit after communicating with FDA
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.